Jazz Pharmaceuticals Bolsa (NASDAQ: JAZZ)

Últimas noticias sobre Jazz Pharmaceuticals (NASDAQ:JAZZ) Bolsa

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board
Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue
Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025
DUBLIN, Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. The Board will commence a formal search process to identify a new CEO, which is anticipated to conclude within 12 months. Mr. Cozadd will retire as CEO once a successor has been appointed and will continue serving as Chairperson of the Board of Directors, providing ongoing leadership and strategic guidance to the Company. Jazz remains on track to meet its full year 2024 total revenue guidance of between $4.0 billion and $4.1 billion.

News

Guidance

Management

JAZZ

Jazz Pharmaceuticals Announces CEO Succession Plan; Bruce Cozadd, Co-Founder, Chairperson And CEO, Plans To Retire As CEO Upon Appointment Of Successor By The End Of 2025; Will Continue As Chair Of The Board; Jazz Remains On Track To Meet Its FY24 Total Revenue Guidance Of Between $4B-$4.1B

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and maintains $163 price target.

Price Target

Reiteration

Analyst Ratings

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Maintains $163 Price Target

RBC Capital analyst Gregory Renza reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and maintains $179 price target.

RBC Capital Reiterates Outperform on Jazz Pharmaceuticals, Maintains $179 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

The majority of caregivers of patients with tuberous sclerosis complex (TSC) say they plan to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and communication. That's according to data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, announced by Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>). 
New data on Epidiolex is being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California via nine company-sponsored posters.
Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was <a href="https://www.benzinga.com/general/biotech/21/05/20989747/jazz-pharmaceuticals-closes-on-acquisition-of-gw-pharma-adds-cbd-drug-epidiolex-to-portfolio">acquired by</a> Jazz Pharmaceuticals in 2021. 
Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved for treating seizures related to <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures">tuberous sclerosis complex</a>, a rare genetic disorder that causes non-cancerous tumors to grow in many parts of the body, including the brain, skin, heart, eyes, kidneys and lungs.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40527455/the-only-fda-approved-cbd-treatment-for-severe-epilepsy-completes-key-phase-3-trial-in-japan-des">The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
&#8220;Our real-world data presentations at AES 2024, including novel findings from the BECOME-LTC, BECOME-TSC and EpiCom studies, demonstrate the meaningful impact of Epidiolex in the treatment of patients with rare epilepsies,&#8221; said Sarah Akerman, MD, head of neuroscience global medical and scientific affairs of Jazz Pharmaceuticals. &#8220;These findings increase our understanding of Epidiolex&#8217;s benefits beyond seizure control, addressing unmet needs across a range of epilepsy syndromes for people living with rare epilepsies and demonstrating reproducibility and consistency of effect across different populations.&#8221;
Other highlights include:
<ul>
<li>Among 102 nurses surveyed, 85% reported a reduction in overall frequency of any seizure type after Epidiolex initiation, with 49% reporting a greater than 50% reduction, according to results from the BECOME-LTC survey.</li>
<li>Demonstrated reduced caregivers&#8217; need for additional support of their dependents&#8217; physical, emotional and behavioral care after Epidiolex initiation and characterized improvements in their dependents&#8217; well-being as well as caregivers&#8217; experiences, results from CARE-EpiC (Caregiver Analysis of Real-world Epidiolex in Epilepsy Context), a cross-sectional caregiver survey showed.</li>
<li>TSC-associated neuropsychiatric disorders (TAND)-associated outcomes demonstrated improvements after initiating adjunctive Epidiolex treatment in the severity of behavioral problems in patients with TSC as reported by the TAND Self-Report Quantified Checklist and Aberrant Behavior Checklist, according to the analysis of the EpiCom trial.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/02/30686971/cbd-based-life-changing-drug-for-tuberous-sclerosis-patients-epidiolex-now-available-via-england">CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England&#8217;s NHS</a></li>
</ul>

Cannabis

Health Care

CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements

Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms
Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex&#xAE;)&nbsp;surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex caregivers
For U.S. media and investors only
DUBLIN, Dec. 6, 2024 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced nine company-sponsored Epidiolex&#xAE;&nbsp;(cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California.
Data presented at the meeting includes updated analyses of real-world data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, which characterizes and quantifies seizure and non-seizure outcomes in patients with epilepsy and tuberous sclerosis complex (TSC) treated with&nbsp;Epidiolex. An additional presentation showcases data from the BECOME-LTC survey, which evaluated the perspectives of nurses who care for patients with epilepsy in long-term care (LTC) facilities and group homes, reporting improvements in seizure frequency and in certain non-seizure outcomes associated with Epidiolex treatment. Further, the first presentation of data from the EpiCom trial, a prospective, interventional trial evaluating the impact of adjunctive Epidiolex on TSC-associated neuropsychiatric disorders (TAND), revealed improvements in behavioral symptom severity following treatment initiation.

Biotech

General

Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex Benefits And Broad-Spectrum Efficacy In Treatment-Resistant Epilepsies At AES 2024 Annual Meeting

Jazz Pharmaceuticals Announced That Zanidatamab-hrii (Ziihera) 50 Mg/Ml For Injection For Intravenous Use Is Recommended By The National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As A Category 2A Treatment Option For Biliary Tract Cancers

Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment
DUBLIN, Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) from&nbsp;December 10-13 and 13 abstracts at the 66th Annual&nbsp;American Society of Hematology&nbsp;(ASH) Annual Meeting from&nbsp;December 7-10.

Jazz Pharmaceuticals To Present Advancements In Solid Tumors And Blood Cancer Research At San Antonio Breast Cancer Symposium And American Society Of Hematology Annual Meeting From December 7-10

On Tuesday, Axsome Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42185380/axsome-therapeutics-announces-axs-12-achieves-primary-endpoint-in-encore-long-term-phase-3-trial-i" rel="noreferrer noopener">Phase 3 ENCORE trial</a>.
AXS-12 was also well tolerated with long-term dosing, and its safety profile was consistent with that observed in previously completed trials.
The primary endpoint was achieved with patients randomized to switch to placebo experiencing a mean increase of 10.29 cataplexy attacks per week compared to a mean increase of 1.32 attacks per week for patients randomized to continue AXS-12 treatment at 3 weeks (p=0.017).
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39891953/axsome-therapeutics-cns-portfolio-poised-for-major-growth-analyst-predicts-strong-f" rel="noreferrer noopener">Axsome Therapeutics&#8217; CNS Portfolio Poised for Major Growth &#8211; Analyst Predicts Strong Future</a>
AXS-12 resulted in statistically significant benefit in cognition compared to placebo.
A higher number of patients who switched to placebo experienced worsening on the NSAQ Ability to Concentrate item compared to those continuing on AXS-12 (52.6% versus 14.3%) at 3 weeks (p=0.011).
A statistically significant improvement in narcolepsy overall was observed compared to placebo.
More patients randomized to switch to placebo reported worsening of their narcolepsy compared to those continuing on AXS-12 (52.6% versus 16.7%) at 3 weeks (p=0.024).
During the long-term open-label treatment portion of the trial, patients experienced substantial and sustained improvement of cataplexy with AXS-12 treatment.
Patients experienced a 71% reduction from baseline in mean weekly cataplexy attacks at 1 month with AXS-12 treatment, which was sustained with long-term treatment, resulting in a 77% reduction at 6 months.
Long-term open-label treatment with AXS-12 resulted in substantial improvements in excessive daytime sleepiness. Mean scores were reduced by 5.6 points at 1 month, with this improvement maintained with long-term treatment, resulting in a mean reduction of 7.3 points at 6 months.
William Blair views the safety profile of AXS-12 as a key differentiator from Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Xyrem. The analyst reiterates the Outperform rating on Axsome.
&#8220;Ultimately, we believe AXS-12 is both an approvable and effective therapy, with the data released today building on both the efficacy and long-term safety of the product,&#8221; the analyst writes.
William Blair conservatively models $440 million in peak AXS-12 sales, relative to growing Wakix sales of $582 million in 2023, and says the asset is undervalued with investor focus on data for AXS-05 in Alzheimer's disease agitation expected before year-end.
Price Action: AXSM stock is up 2.5% at $99.46 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42216863/nvidia-intel-suppliers-rethink-mexico-operations-amid-trumps-tariff-threat" target="_blank" rel="noreferrer noopener">Nvidia, Intel Suppliers Rethink Mexico Operations Amid Trump&#8217;s Tariff Threat</a></li>
</ul>
Image via Pixabay.

Analyst Color

Equities

Trading Ideas

AXSM

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

On Wednesday, the FDA granted accelerated approval to Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a href="https://www.benzinga.com/pressreleases/24/11/n42101689/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-a" target="_blank" rel="noreferrer noopener">biliary tract cancer (BTC)</a>.
Ziihera&nbsp;was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41338366/jazz-pharmaceuticals-zepzelcatecentriq-combo-regimen-can-potentially-delay-disease-progression-ex" rel="noreferrer noopener">Jazz Pharmaceuticals&#8217; Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer</a>
The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe.
In late 2022, Zymeworks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) entered into a license and collaboration agreement with Jazz Pharmaceuticals for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia Pacific territories previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">licensed by Zymeworks</a>.
Under the Jazz license and collaboration agreement terms, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
Zymeworks says the approval represents the first FDA-approved therapy in its pipeline and validates the company&#8217;s Azymetric bispecific platform technology.
Price Action: JAZZ stock closed at $119.24 on Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease" target="_blank" rel="noreferrer noopener">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a></li>
</ul>
Photo: Shutterstock

Large Cap

ZYME

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $166 to $163.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $163

Jazz Pharmaceuticals and Zymeworks shares are trading higher after announcing their Zihera collaboration secured FDA approval to treat HER2-positive biliary tract cancer in adults.

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of
<ul>
<li>Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.</li>
<li>Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial</li>
<li>Company to host investor webcast on Dec. 11, 2024</li>
</ul>
In late 2022, Zymeworks entered into a license and collaboration agreement with Jazz Pharmaceuticals Ireland Limited (a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as Jazz), for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia Pacific territories previously licensed by Zymeworks. This collaboration allowed the Company to leverage Jazz's global commercial infrastructure, together with BeiGene's complementary strengths in certain Asia Pacific countries, to enable the global, rapid advancement of zanidatamab in multiple tumor types with the potential to provide a foundational HER2-targeted therapy for patients with difficult-to-treat cancers and limited treatment options. Under the terms of the Jazz license and collaboration agreement, Zymeworks has earned a milestone payment of $25M based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500M in regulatory milestone payments and $862.5M in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.

Reported Earlier, Jazz Pharmaceuticals Secures FDA Approval For Ziihera (zanidatamab-hrii) To Treat HER2-Positive Biliary Tract Cancer In Adults

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $154 to $162.

Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $162

Disclosed on November 13, Neena M Patil, EVP &amp; Chief Legal Officer at Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: After conducting a thorough analysis, Patil sold 3,700 shares of Jazz Pharmaceuticals. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001232524/000176558124000088//Archives/edgar/data/1232524/000176558124000088/0001765581-24-000088-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total transaction value is $456,617.
During Thursday's morning session, Jazz Pharmaceuticals shares down by 0.5%, currently priced at $127.01.
<h3>Get to Know Jazz Pharmaceuticals Better</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 8.52% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 89.42%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Jazz Pharmaceuticals's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 3.5.
</li>
</ul>
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.49.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 18.08 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.18 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 8.65, Jazz Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001232524">Check Out The Full List Of Jazz Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Neena M Patil Executes Sell Order: Offloads $456K In Jazz Pharmaceuticals Stock

Six years after the United Kingdom legalized medical marijuana, families struggling to obtain life-saving medicine through the National Health Service (NHS) returned to Westminster on Tuesday, demanding change. They displayed photos of their loved ones who experienced significant improvement with medical marijuana, <a href="https://businessofcannabis.com/parents-of-children-with-epilepsy-demand-urgent-nhs-reform-for-cannabis-access/">reports</a> the Business of Cannabis.
<h2 class="wp-block-heading">NHS Is Failing Patients</h2>
Parents of children suffering from treatment-resistant epilepsy say their children have achieved seizure freedom with medical marijuana, thanks to cannabis' effectiveness compared as to conventional treatments.
Those gathered at Westminster criticizes the lack of NHS prescriptions, especially for children with epilepsy. Only about 50 children have access to private prescriptions due to the limited availability of pediatric neurologists willing to prescribe. Campaigners argued that the NHS is failing patients and called for a change.
"When prescription cannabis was legalized six years ago, this was not the situation that patients were promised or expected," said co-chairs of the Cannabis Industry Council, Dr Callie Seaman and Jamie Bartley. "It's time for the NHS to take action to expand public funding of cannabis medicines. A clear pathway should be established for patients to access prescriptions via the NHS, while private prescriptions could also be reimbursed by the public purse."
A Department of Health and Social Care spokesperson said: "Licensed cannabis-based medicines are routinely funded by the NHS where there is clear evidence of their quality, safety, and effectiveness. The NHS is taking an evidence-based approach to unlicensed cannabis-based treatments to ensure they are proved safe and effective before they can be considered for roll out more widely."
The need for cannabis as medicine in the U.K. was first highlighted by two cases involving children with severe epilepsy: <a href="https://www.benzinga.com/markets/cannabis/22/12/30175937/only-cannabis-stops-harrys-constant-seizures-says-mom-he-gets-it-for-free-thanks-to-i-am-billy-c">Billy Caldwell</a> and Alfie Dingley who were both using cannabis low-dose THC oil to treat their seizures.
While it is possible to access medical marijuana through the NHS, this rarely occurs and only in severe cases of epilepsy, chemotherapy-induced nausea or certain cases of muscle stiffness associated with MS. Since medical marijuana is not widely available through the NHS, many families struggle to <a href="https://www.benzinga.com/markets/cannabis/23/10/35388605/europes-high-uk-parents-need-nhs-help-for-daughters-seizures-thc-mmj-flowers-in-switzerland-more" target="_blank" rel="noreferrer noopener">afford life-saving medicine</a> for their children.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41492967/medical-marijuana-for-chronic-pain-could-cut-uks-national-health-costs-by-5-19b-annually-improvi">Medical Marijuana For Chronic Pain Could Cut UK&#8217;s National Health Costs By $5.19B Annually, Improving Health Outcomes</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Per a report, new figures show the lack of prescribing of both unlicensed and licensed medical marijuana medicines, such as <a href="https://www.benzinga.com/topic/epidiolex">Epidiolex</a> and Sativex in the NHS. According to the NHS Business Service Authority, ‘fewer than five' patients have an NHS prescription for unlicensed cannabis medicines, while the <a href="https://www.benzinga.com/markets/cannabis/24/10/41431474/as-uk-medical-marijuana-market-booms-cannabis-clinics-receive-good-practice-guide">private sectors booms</a> with more than 35,000 medical cannabis patients.
Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was <a href="https://www.benzinga.com/general/biotech/21/05/20989747/jazz-pharmaceuticals-closes-on-acquisition-of-gw-pharma-adds-cbd-drug-epidiolex-to-portfolio" target="_blank" rel="noreferrer noopener">acquired by</a> Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) in 2021. Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures" target="_blank" rel="noreferrer noopener">for treating seizures related to tuberous sclerosis complex</a>.
A Freedom of Information request reveals that no NHS trusts have prescribed cannabis flower, and only 27% prescribe licensed medical marijuana medicines, such as Epidiolex.
Continue reading on <a href="https://businessofcannabis.com/parents-of-children-with-epilepsy-demand-urgent-nhs-reform-for-cannabis-access/">Business of Cannabis</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/06/32693057/uk-moms-concern-as-no-doctor-will-prescribe-cannabis-for-her-daughters-300-daily-seizures">UK Mom&#8217;s Concern As No Doctor Will Prescribe Cannabis For Her Daughter&#8217;s 300 Daily Seizures</a></li>
</ul>
Photo: Benzinga edit of images by Marcin Nowak and Kimzy Nanney on Unsplash

Eurozone

UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy

TD Cowen maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and lowers the price target from $200 to $195.

TD Cowen Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $195

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Jazz Pharmaceuticals: Should Sing A Better Tune In 2025

Carillon Chartwell Short Duration High Yield Fund Q3 2024 Commentary

In the expanding oncology market, Exelixis (EXEL) is gaining attention with its strong pipeline and impressive stock performance. With a clear focus on cancer treatment innovation and a growing market presence, is the company set to lead the future of cancer care and treatment? Read more… Exelixis, Inc. (<a href="https://stocknews.com/stock/EXEL/">EXEL</a>) is quickly establishing itself as a major force in the rapidly evolving cancer treatment landscape. Reporting exceptional results for its fiscal third quarter, the company has not only exceeded analyst expectations but is also driving forward with a strong portfolio of innovative therapies.
At the heart of EXEL's success is its impressive pipeline of emerging cancer therapies. The company's flagship product, CABOMETYX&#xAE;, continues to make waves alongside promising treatments like Zanzalintinib, XB010, and XL495. With many of these therapies still in trial phases or awaiting FDA approvals, EXEL is relentlessly working to create better treatment options.
EXEL's achievements are clearly reflected in its stock performance, which has been nothing short of remarkable. In the last three months, the stock surged 31.3%, while over the past year, it rose by an impressive 54.1%, closing the last trading session at $36.07.
So, let us dive into the factors that could shape EXEL's performance in the near future.
Recent Developments
On October 14, EXEL <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-and-merck-sign-clinical-development-collaboration">announced a collaboration</a> with Merck &amp; Co., Inc. (<a href="https://stocknews.com/stock/MRK/">MRK</a>) to evaluate the combination of EXEL's zanzalintinib with MRK's KEYTRUDA&#xAE; for the treatment of patients with head and neck squamous cell carcinoma and with renal cell carcinoma. The collaboration has the potential to elevate EXEL's already impressive cancer treatment pipeline.
Earlier this year, on August 6, EXEL caught the attention of the medical community with the <a href="https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-us-food-and-drug-administration-fda-accepted">FDA's acceptance of cabozantinib</a> for the treatment of adults with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors.
The acceptance gives the company a powerful tool in the fight against neuroendocrine tumors, one of the more complex and challenging cancer types. This step also strengthens EXEL's position in the oncology market, with more treatment options to offer.
Sound Historical Growth
Over the past three years, EXEL has demonstrated consistent growth across key financial metrics. Its revenue grew at a CAGR of 18.4%, while EBITDA rose faster at 45%. Operational income (EBIT) and total assets expanded at CAGRs of 46.3% and 6.5%, respectively.
Moreover, net income surged at a CAGR of 41.7%, and EPS climbed even higher at 44.8%, showcasing robust profitability.
Strong Financials
For the fiscal 2024 third quarter that ended September 30, EXEL's total revenues increased 14.3% year-over-year to $539.54 million. Its income from operations came in at $136.08 million, compared to a loss from operations of $17.58 million in the previous year's quarter.
Additionally, non-GAAP net income and non-GAAP net income per share rose 322.6% and 370% from the prior year's quarter to $135.66 million and $0.47, respectively.
Favorable Analyst Estimates
Analysts predict EXEL's revenue and EPS for the fiscal fourth quarter ending December 2024 to increase 17.1% and 42.4% year-over-year to $561.61 million and $0.38, respectively. In addition, the company exceeded the consensus revenue and EPS estimates in three of the four trailing quarters.
For the full fiscal year 2024, ending December 2024, EXEL's revenue and EPS are expected to rise 18.1% and 162.6% from the previous year, reaching $2.16 billion and $1.71, respectively.
Discounted Valuation
EXEL is currently trading at a forward P/E of 21.13x, which is 28% lower than the industry average of 29.33x. Moreover, the stock's forward <a href="https://www.investopedia.com/terms/e/ebit-ev-multiple.asp">EV/EBIT multiple</a> stands at 15.89, 4% lower than the industry average of 16.55x. This indicates that EXEL is undervalued compared to the broader market, offering potential upside for investors.
Robust Profitability
EXEL's trailing-12-month gross profit margin of 96.25% is 65% higher than the industry average of 58.35%. Its trailing-12-month EBITDA margin stands at 30.55%, 415.7% higher than the industry average of 5.92%.
Additionally, EXEL's trailing-12-month levered FCF margin of 20.72% outperforms the industry average of 2% by 933.5%. Moreover, the company boasts a trailing-12-month asset turnover ratio of 0.70x, which is 69.6% above the sector average of 0.41x.
POWR Ratings Reflects Optimism
EXEL's strong fundamentals are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of A, which equates to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by taking into account 118 different factors, with each factor weighted to an optimal degree.
EXEL earns an A grade for Value, driven by its discounted valuation metrics relative to the industry average. It also holds an A for Quality, supported by profitability measures that exceed industry benchmarks. Additionally, EXEL holds a B grade for Sentiment, reflecting the positive outlook from analyst estimates.
Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, the stock is ranked #5 out of 334 stocks. Beyond what is stated above, we have also given EXEL grades for Momentum, Growth, and Stability. Get all EXEL ratings <a href="https://stocknews.com/stock/EXEL/">here</a>.
Bottom Line
EXEL is on the verge of significant success as more and more of the drugs in its pipeline are gaining approval from the FDA and other global regulatory bodies. In addition to its promising pipeline, the company boasts a strong portfolio of cancer therapies that are already making a mark in the market.
With these treatments gaining traction, the company is exceptionally well-positioned to benefit from the rapid growth of emerging cancer therapies. What sets EXEL apart is its combination of high profitability, strong financials, and a valuation that is currently lower than the industry average.
This unique positioning has garnered attention from analysts, who see great potential for the company in the coming years. Thus, now might be the ideal time to consider adding EXEL to an investment portfolio.
How Does Exelixis, Inc. (EXEL) Stack Up Against Its Peers?
Although EXEL's near-term outlook appears sound, it may be worthwhile to explore its industry peers, who also exhibit strong POWR Ratings. So, consider these A (Strong Buy) stocks from the Biotech industry:
Gilead Sciences, Inc. (<a href="https://stocknews.com/stock/GILD/">GILD</a>)
Genmab A/S (<a href="https://stocknews.com/stock/GMAB/">GMAB</a>)
Jazz Pharmaceuticals plc (<a href="https://stocknews.com/stock/JAZZ/">JAZZ</a>)
To explore more A or B-rated Biotech stocks, <a href="https://stocknews.com/category/biotech/">click here</a>.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>
<hr />
EXEL shares were unchanged in premarket trading Tuesday. Year-to-date, EXEL has gained 50.35%, versus a 28.87% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Aanchal Sugandh</h2> <img src='https:/wp-content/uploads/2022/12/Aanchal-Sugandh_Headshot.jpg' style="float:left; padding:5px;width:125px;">Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program.

She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns.<a href="https://stocknews.com/authors/?author=aanchal-sugandh">More...</a>The post <a href=https://stocknews.com/news/exel-gild-gmab-jazz-mrk-is-exelixis-positioned-to-capitalize-on-emerging-cancer-therapies/>Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

Is Exelixis Positioned to Capitalize on Emerging Cancer Therapies?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Jazz Pharmaceuticals (JAZZ – Research Report), Nater...

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Natera (NTRA) and Neumora Therapeutics, Inc. (NMRA)

Zymeworks says it has enough cash to operate through H2 2027

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sotera Health (SHC – Research Report), Jazz Pharmace...

Analysts Offer Insights on Healthcare Companies: Sotera Health (SHC), Jazz Pharmaceuticals (JAZZ) and Karyopharm Therapeutics (KPTI)

RBC Capital analyst Gregory Renza maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) on January 7 and set a price target of $...

RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

3 Oversold Biotech Names

AVDL

BGNE

CWEN

EXEL

FOLD

FTAI

GILD

GMAB

KNTK

KPTI

NMRA

NTRA

RHHBY

VICI

VKTX

Press Releases

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Earnings

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024

Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)

Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting

Jazz Pharmaceuticals Announces CEO Succession Plan

Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

Noticias

Últimas noticias sobre Jazz Pharmaceuticals (NASDAQ:JAZZ) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL